Focal Therapy for Localised Prostate Cancer
|
|
- Mary Armstrong
- 7 years ago
- Views:
Transcription
1 Focal Therapy for Localised Prostate Cancer SOGUG 2012 Miss Louise Dickinson NIHR Academic Clinical Fellow/ SpR in Urology Division of Surgery and Interventional Science, UCL & Department of Urology, University College Hospital London
2
3 Over-treatment
4
5 The errors that result from the current strategy... Clinically indolent cancers are identified by chance Clinically significant lesions are missed Important cancers are incorrectly classified as unimportant Men undergo whole-gland treatment which carries harm
6 The Potential Solution...? Not all cancer has the potential to progress to invasive and metastatic cancer Novel imaging and biopsy techniques can identify those lesions that are likely to progress Selective therapy to Clinically Significant lesions alone could be as effective as whole-gland treatment and carry less harm
7 Improvements in imaging and biopsy techniques are driving a change in practice
8 Improved detection and localisation
9
10
11 Increasing global interest
12 Focal Therapy A potential strategy for reducing treatment related morbidity whilst offering cancer control A strategy that follows the approach taken for other solid organ tumours Breast Renal Penile
13 Cryotherapy Hemiablation Courtesy Lambert et al, 2007
14 Cryotherapy Focal Therapy Series Reported Onik et al (2009) (Endocare) Ellis et al (2007) (Endocare) Lambert et al (2007) (Oncura) Bahn et al (2006) (Endocare) Crawford/ Barqawi (2009) (Endocare) COLD Registry (2009) (Endocare) No Therapy Hemi Hemi Hemi Hemi Focal Focal/Partial Biopsy Template TRUS TRUS TRUS +Doppler Template TRUS Mean PSA (ng/ml) / (range 1-13) /- 4.1 Gleason Score 6 </=8 </=7 </=7 </=7 </=8 Potency 85% 70.6% 70.8% 89% 83% 65% Incontinence 0% 3.6% 0% 0% - 2.8% F/U (mean, months) Disease control 93% NED 76.7% (biopsy) 88% (>50% nadir reduction) 96% (biopsy) 92% (ASTRO) 97% (biopsy at 12/12) 4.5% (36/295) 25% (36/199) 83% (ASTRO) 14
15 High Intensity Focused Ultrasound
16 UCL Trials in Focal Therapy using HIFU Hemi-HIFU Trial Focal-HIFU Trial Lesion Control HIFU Trial
17 Prostate Mapping Biopsies Barzell and Onik, 2009
18 Hemi-HIFU Trial... 89% of men achieved the trifecta status of pad-free, leak-free continence, erections sufficient for intercourse and cancer control at 12 months.
19 Lancet Oncology, April 2012
20 Focal HIFU results
21 The INDEX Study PIs: Ahmed/Emberton Co-ordinator: Dickinson NCRN-adopted Industry supported Ahmed, Dickinson, Emberton Ogden, Parker, Thompson, Van As, Abel, Hrouda, Winkler Brewster, Leslie Hindley Persad van der Meulen Mulhall
22 140 men with localised PCa Focal HIFU 1-2 weeks TWOC, contrast-mri 6 weeks, 3*, 6 and 9* months: PSA, questionnaires 12 months: mp-mri, TRUS biopsy of treated side 18*, 24, 30* month follow up 36 months mp-mri, Template biopsies, 38* months Tissue Biobank Imaging Databank Histology Biobank Serum, germline Kallikreins PTEN glycoproteins Imaging Biomarkers MRI CAD USS Tissue Characterisation Histological Biomarkers discovery TMA 22
23 Vascular targeted photodynamic therapy European Multi-centre Phase III Randomised Controlled Trial Low risk disease Active surveillance versus Photodynamic therapy
24 6 month biopsy negative for cancer
25 Other potential focal therapies February 2012
26 Other potential focal therapies
27 The Future for Image Targeted Therapies?
28 Pre-operative contouring of lesion
29 Biomechanical model generation MR contours used to form a finite element mesh (FEM) model Gland deformation Probe- (or MR-coil-) induced prostate deformation
30 Intra-operative contouring
31 n = 17 with additional treatment margins in 10/17 Average time = 7 minutes (4 16)
32 Conclusions Focal therapy is demonstrating encouraging genito-urinary functional outcomes within early, small, short-term studies Medium and long-term outcomes are awaited from prospective clinical trials and prospective registries Advances in techniques for localising clinically significant disease may allow more targeted diagnostics and therapies
33 Minimally-Invasive Prostate Intervention (MIPI) Group Division of Surgery and Interventional Science, UCL Prof Mark Emberton (Honorary Consultant Urologist) Mr Hashim Uddin Ahmed (MRC Clinician Scientist) Mrs Caroline Moore (Clinical Lecturer) Mr Manit Arya (Senior Clinical Lecturer and Consultant) Mr Paul Cathcart (Senior Clinical Lecturer and Consultant) Mr Paras Singh (NIHR Academic Clinical Fellow) Miss Louise Dickinson (NIHR Academic Clinical Fellow) Miss Lucy Simmons (Research Fellow) Mr Massimo Valerio (EAU Research Fellow) Department of Academic Radiology, UCLH NHS Trust Dr Clare Allen (Consultant Radiologist) Dr Alex Kirkham (Consultant Radiologist Dr Shonit Punwani (Consultant Radiologist) Dr Rowland Illing (Academic Radiology Registrar) National Medical Laser Centre Professor Steve Bown Dr Sandy Mosse Department of Histopathology, UCLH NHS Trust Dr Alex Freeman (Consultant Histopathologist) Dr Charles Jameson (Consultant Histopathologist) Centre for Medical Imaging Science, UCL Professor David Hawkes Dr Dean Barratt (Royal Academy Senior Research Fellow) Mr Yipeng Hu (MSc Student) Clinical Effectiveness Unit, RCS(England) & LSHTM Professor Jan van der Meulen Dr Susan Charman (Senior Lecturer in Epidemiology) Veeru Kasivisvanathan (Academic Clinical Fellow in Urology) Eleni Anastasiadis (Academic Clinical Fellow in Urology) Academic and Charity Supporters Commercial Supporters
Prostate cancer what do we see and how do we see it?
Prostate cancer what do we see and how do we see it? Caroline Moore MD FRCS(Urol) Consultant Urologist, University College Hospital Senior Clinical Researcher, Division of Surgical & Interventional Science,
More informationStudy Protocol. Short Title: Focal Therapy for Prostate Cancer using HIFU. INDEX Study Group. Protocol code. Version 4
A Multi-Centre Prospective Single Arm Intervention Trial Evaluating Focal Therapy using High Intensity Focused Ultrasound (Sonablate 500) for Localised Prostate Cancer Study Protocol Short Title: Focal
More informationFocal therapy for prostate cancer: seriously or seriously? Disclosures
Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationTargeted Focal (Subtotal) Therapy for Early Stage Prostate Cancer
Targeted Focal (Subtotal) Therapy for Early Stage Prostate Cancer Duke K. Bahn, MD Prostate Institute of America (www.pioa.org) Ventura, California 888-234-0004 Published in PAACT newsletter Introduction:
More informationAdvances in Prostate Imaging and Ablative Treatment of Prostate Cancer
Provided by the NYU Post-Graduate Medical School Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer Friday Saturday June 19 20, 2015 New York City Register online: med.nyu.edu/cme/mi
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationFocal Therapy for Localized Prostate Cancer: A Phase I/II Trial
Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial H. U. Ahmed,*, A. Freeman, A. Kirkham, M. Sahu, R. Scott, C. Allen, J. Van der Meulen and M. Emberton From the Division of Surgery and Interventional
More informationSaturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies
Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies John F. Ward, MD Assistant Professor University of Texas M. D. Anderson Cancer Center Ablation
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationAdvances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
More informationReal Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer
Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer A/Prof Celi Varol and Dr Orit Raz Uro-Oncologist Nepean and Macquarie Hospital Trial at Macquarie University Hospital Ethics board
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationREGISTRATIONS. Tel: 0207 670 4777 (Mon Fri, 09:00 17:00) SAE NOTIFICATION
GENERAL INFORMATION Acronym: PROMIS Title: Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterisation of Prostate Cancer This document describes a Health Technology
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationRole of MRI in the Diagnosis of Prostate Cancer, A Proposal
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationNEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationReview of Focal Therapy for Localized Prostate Cancer
Review of Focal Therapy for Localized Prostate Cancer Frances M. Martin and John F. Ward* Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 2 PCRI Insights www.pcri.org
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationThe PLCO Trial Not a comparison of Screening vs no Screening
PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationResearch Strategy 2012 2020
Research Strategy 2012 2020 Foreword Acknowledgements We are particularly indebted to Professor David Neal and Professor Michael Olson for their expert assessment of the trends, gaps and bottlenecks in
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More informationKim Mammen Abhinav Jaiswal Chris3an Medical College & Hospital Ludhiana India
Kim Mammen Abhinav Jaiswal Chris3an Medical College & Hospital Ludhiana India } In the case of prostate cancer, a new, more conserva3ve form of monitoring called Ac3ve Surveillance is emerging which might
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationScreening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationA guide to prostate cancer clinical trials
1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationDiagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls
Diagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls Mark Notley, MD; Jinxing Yu, MD; Ann S. Fulcher, MD; Mary A. Turner, MD; Don Nguyen, MD Virginia Commonwealth
More informationProstate Cancer Guide. A resource to help answer your questions about prostate cancer
Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online
More informationThe introduction of breast-sparing surgery (ie, Male Lumpectomy : Focal Therapy for Prostate Cancer Using Cryoablation
Male Lumpectomy : Focal Therapy for Prostate Cancer Using Cryoablation Gary Onik, David Vaughan, Richard Lotenfoe, Martin Dineen, and Jeff Brady The introduction of breast-sparing surgery (ie, lumpectomy
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationPSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationLocalised prostate cancer
Diagnosis Specialist Nurses 0800 074 8383 prostatecanceruk.org 1 Localised prostate cancer In this fact sheet: What is localised prostate cancer? How is localised prostate cancer diagnosed? What do my
More informationProstate Cancer. Patient Information
Prostate Cancer Patient Information 1 The Prostate & Prostate Cancer The prostate is a small gland in the male reproductive system, approximately the size and shape of a walnut. It is located directly
More informationPCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
More informationCYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
More informationHealth Policy Advisory Committee on Technology
Health Policy Advisory Committee on Technology Technology Brief MRI screening for prostate cancer March 2015 State of Queensland (Queensland Department of Health) 2015 This work is licensed under a Creative
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationGuidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer
Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty
More informationScreening for Prostate Cancer
Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationA start to help you understand prostate cancer
A start to help you understand prostate cancer If you are reading this because you have worries or concerns about yourself or someone you know then the best thing to do is make an appointment with your
More informationNEWSLETTER Nicholas Brook Urology
For Appointments Call : 08 8267 2200 January/February 2014 NEWSLETTER Nicholas Brook Urology Latest Urology News Welcome to the Nicholas Brook Urology newsletter January 2014. Nick Brook Urology on Ward
More informationFor further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.
Prostate Cancer For many older men, prostate cancer may be present but never cause symptoms or problems and many men will die with their prostate cancer rather than of their prostate cancer. Yet it remains
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationFocal Treatments for Prostate Cancer
Name of Policy: Focal Treatments for Prostate Cancer Policy #: 596 Latest Review Date: September 2015 Category: Surgery Policy Grade: C Background/Definitions: As a general rule, benefits are payable under
More informationFocus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening?
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy
More informationPROSTATE CANCER 101 WHAT IS PROSTATE CANCER?
PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in
More informationMagnetic Resonance Imaging Targeted Biopsy of the Prostate
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationProstate Cancer Screening. Dr. J. McCracken, Urologist
Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationd EFFECTIVE DATE: 10 06 2015 POLICY LAST UPDATED: 07 21 2015
Medical Coverage Policy Focal Treatment for Prostate Cancer d EFFECTIVE DATE: 10 06 2015 POLICY LAST UPDATED: 07 21 2015 OVERVIEW Prostate cancer is the second most common cancer diagnosed among men in
More informationBJUI. Overall, 71% had no evidence of disease following salvage HIFU. RESULTS. Study Type Therapy (case series) Level of Evidence 4
2008 The Authors. Journal compilation 2008 BJU International Original Article HIFU AS SALVAGE THERAPY FOR RECURRENT PROSTATE CANCER AFTER EBRT ZACHARAKIS et al. BJUI BJU INTERNATIONAL The feasibility and
More informationThis document contains three General Surgery placement descriptions:
This document contains three General Surgery descriptions: North Central Thames Foundation School (NCTFS) Individual Description - Basildon and Thurrock University Hospitals NHS Foundation Trust type of
More informationMALE LUMPECTOMY: FOCAL THERAPY IS THE FUTURE OF PROSTATE CANCER TREATMENT
MALE LUMPECTOMY: FOCAL THERAPY IS THE FUTURE OF PROSTATE CANCER TREATMENT GARY ONIK, MD THE ONIK PROSTATE CANCER CENTER - AVENTURA, FL CONTACT: KAREN BARRIE, MS (847) 502-1414 OR EMAIL: BARRIEMEDMARKETING@GMAIL.COM
More informationRenal Cancer Expression of Interest - Detailed Proposals
Renal Cancer Expression of Interest - Detailed Proposals Trust Clinical Lead Managerial Lead Royal Free London NHS Foundation Trust Robin Woolfson, Divisional Clinical Director Sue Lyons, Divisional Director
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationPATIENT GUIDE. Localized Prostate Cancer
PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is
More informationCombined Harvard Urologic Oncology Fellowship Program
Combined Harvard Urologic Oncology Fellowship Program 1 Goal: Department of Urology To reduce the disease burden for patients with urologic issues by improving: Clinical Care Teaching Research 2 History
More informationFocal Treatments for Prostate Cancer
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Focal Treatments for Prostate Cancer Number 8.01.61 Effective
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationBard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers
Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More information10/15/2012. Innovation, Translation, Impact. Quentin Pankhurst
Innovation, Translation, Impact Quentin Pankhurst A cross-faculty consortium for the promotion of innovative and translational research in medical technologies Medical Technologies Used to diagnose, monitor
More informationBreast Cancer Care & Research
Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female
More informationTreating Localized Prostate Cancer A Review of the Research for Adults
Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized
More informationKey Messages for Healthcare Providers
Cancer Care Ontario: Prostate Cancer Screening with the Prostate- Specific Antigen (PSA) Test Key Messages for Healthcare Providers Considerations for men at average risk Avoid prostate-specific antigen
More informationThe RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial of treatment after surgery for prostate cancer
Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire HP21 8AL Tel: 01296 315 908 www.buckshealthcare.nhs.uk The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationDOCTOr. Doctor to HIGHLIGHTS. issue NO. 3 VOLuMe NO. 1
Doctor to DOCTOr issue NO. 3 VOLuMe NO. 1 PROSTATE CANCER is the most common cancer in men, with 233,000 new cases diagnosed per year. Although prostate cancer remains the second leading cause of cancer
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationThis vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years
Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationLocal Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation
Local Salvage Therapies After Failed Radiation for Prostate Cancer James Eastham, MD Memorial Sloan-Kettering Cancer Center New York, New York Biochemical Failure after Radiation ASTRO criteria 3 consecutive
More informationA Woman s Guide to Prostate Cancer Treatment
A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationRobotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology
Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Prostate Cancer Epidemiology: 2009 Estimated new cases: 230,000 Estimated deaths:
More informationREGISTRY OF IRREVERSIBLE ELECTROPORATION FOR THE ABLATION OF PROSTATE CANCER WITH USE OF NANOKNIFE DEVICE
REGISTRY OF IRREVERSIBLE ELECTROPORATION FOR THE ABLATION OF PROSTATE CANCER WITH USE OF NANOKNIFE DEVICE A Multi-Center, International Registry to evaluate the treatment of Prostate Cancer in terms of
More informationBiomarkers for Prostate Cancer. Eric Wallen, MD Department of Urology
Biomarkers for Prostate Cancer Eric Wallen, MD Department of Urology Disclosure MDxHealth Scientific Advisor 55-year-old man: Poor Guy Risk of prostate cancer? 1 in 6 Risk of prostate cancer death? 1 in
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationProstate cancer A guide for newly diagnosed men
Prostate cancer A guide for newly diagnosed men 2 Prostate cancer A guide for newly diagnosed men About this booklet This booklet is for men who have recently been diagnosed with prostate cancer. It is
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationDECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING
DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices
More informationProstate Cancer. Screening and Diagnosis. Screening. Pardeep Kumar Consultant Urological Surgeon
The Royal Marsden Prostate Cancer Screening and Diagnosis Pardeep Kumar Consultant Urological Surgeon Prostate Cancer Screening and Diagnosis 08 02 2013 2 Screening 1 3 Q1.Lots of men have prostate cancer
More informationFiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
More informationDraft Clinical Practice Guidelines. PSA Testing and Early Management of Test-Detected Prostate Cancer
Draft Clinical Practice Guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer Draft November 2014 Prostate Cancer Foundation of Australia and Cancer Council Australia ISBN: This
More informationThe Business of Prostate Cancer Care: A Clinician-Researcher s Perspective
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
More informationProstate Cancer Screening. A Decision Guide for African Americans
Prostate Cancer Screening A Decision Guide for African Americans This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Published
More information